The Bacillus subtilis dihydrofolate reductase (DHFR) gene was expressed in Escherichia coli. The gene product was purified to homogeneity by Butyl-Toyopearl, Toyopearl HW55, and DEAE-Toyopearl column chromatographies, and its molecular properties were compared to those of E. coli DHFR. The specific enzyme activity of the B. subtilis DHFR was 240 units/mg under the standard assay conditions, being about four times higher than that of the E. coli DHFR. Km for coenzyme NADPH was 20.7 microM, a value about three times larger than that of E. coli, whereas Km (1.5 microM) for the substrate, dihydrofolate, was similar to that of E. coli DHFR. This seems to reflect the low homology of the amino acid sequence in residues 61-88 of the two DHFRs where one of the NADPH binding sites is located [Bystrof, C. & Kraut, J. (1991) Biochemistry 30, 2227-2239]. Similar to the E. coli DHFR [Iwakura, M. et al. (1992) J. Biochem. 111, 37-45], the extension of amino acid sequences at the C-terminal end of the B. subtilis DHFR could be attained without loss of the enzyme function or decrease of the protein yield. Thus, the DHFR is useful as a carrier protein for expressing small polypeptides, such as leucine enkephalin, bradykinin, and somatostatin.

Download full-text PDF

Source
http://dx.doi.org/10.1093/oxfordjournals.jbchem.a123811DOI Listing

Publication Analysis

Top Keywords

coli dhfr
16
dihydrofolate reductase
8
bacillus subtilis
8
dhfr
8
subtilis dhfr
8
amino acid
8
coli
6
reductase bacillus
4
subtilis
4
subtilis artificial
4

Similar Publications

Structure and catalytic activity of a dihydrofolate reductase-like enzyme from Leptospira interrogans.

Int J Biol Macromol

January 2025

Center of Excellence for Molecular Biology and Genomics of Shrimp, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand; Center of Excellence in Molecular Crop, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand. Electronic address:

A dihydrofolate reductase (DHFR)-like enzyme from Leptospira interrogans (LiDHFRL) was cloned and the recombinant protein was characterized. Sequence alignment suggested that the enzyme lacked the conserved catalytic residues found in DHFR. Indeed, LiDHFRL did not catalyze the reduction of dihydrofolate by either NADH or NADPH.

View Article and Find Full Text PDF

Molecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors.

BMC Chem

December 2024

Laboratory of Preservation Technology and Enzyme Inhibition Studies, Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India.

Dihydrofolate reductase (DHFR) is an enzyme that plays a crucial role in folate metabolism, which is essential for cell growth and division. DHFR has been identified as a molecular target for numerous diseases due to its significance in various biological processes. DHFR inhibitors can disrupt folate metabolism by inhibiting DHFR, leading to the inhibition of cell growth.

View Article and Find Full Text PDF

In this study 1-vinyl-3-alkyl imidazolium-based ionic liquid monomers (ILs) with different alkyl chain lengths {R = hexyl (A), octyl (B) and decyl (C)} have been synthesized for antibacterial applications. The prepared ILs have been characterized using UV, FT-IR and NMR spectroscopy. The antibacterial activities of the synthesized ILs against Staphylococcus aureus (S.

View Article and Find Full Text PDF

A series of 1,2,4-triazolo[1,5-]pyrimidine-based derivatives were developed and prepared by reacting chalcones - with 3-phenyl-1,2,4-triazole-5-amine (). The novel compounds were analyzed using several spectroscopic techniques, and their antimicrobial efficacies against six pathogens (Gram-negative, Gram-positive, and fungi) were tested. Most of the tested compounds exhibited significant antimicrobial activity compared to ciprofloxacin and fluconazole.

View Article and Find Full Text PDF
Article Synopsis
  • α,β-unsaturated carbonyl compounds, like the newly synthesized CY3, have important applications in pharmaceuticals and exhibit promising antimicrobial and antifungal properties.
  • The study involved synthesizing CY3 and testing its effects against various bacterial and fungal strains, revealing moderate activity and potential for drug development.
  • In-silico analyses showed favorable drug-likeness for CY3, indicating good bioavailability, while molecular docking studies highlighted its strong binding with key proteins involved in bacterial function.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!